Posted by Michael Wonder on 22 Jul 2021
Dupixent (dupilumab injection) receives positive recommendation from CADTH and INESSS for the treatment of severe asthma
22 July 2021 - Recommendation supported by multiple clinical trials that demonstrated a reduced frequency of asthma exacerbations compared to placebo, and a reduction in the need for oral corticosteroids in oral corticosteroid-dependent patients.
Sanofi Canada is pleased to announce that the Canadian Agency for Drugs and Technologies in Health (CADTH) and Institut national d'excellence en santé et en services sociaux (INESSS) issued positive recommendations for the reimbursement of Dupixent (dupilumab injection) for the treatment of severe asthma and oral corticosteroid-dependent asthma and when certain conditions are met.
